<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879265</url>
  </required_header>
  <id_info>
    <org_study_id>IBB11</org_study_id>
    <nct_id>NCT03879265</nct_id>
  </id_info>
  <brief_title>Validation of a NICS Method Using the Culture Medium</brief_title>
  <official_title>Validation of a Noninvasive Chromosome Screening (NICS) Method Using the Culture Medium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate a non-invasive method of chromosomal screening (NICS), based on
      the Multiple Annealing and Looping Based Amplification Cycles- Next-generation Sequencing
      (MALBAC-NGS) technology, in order to determine the chromosomal endowment of a blastocyst from
      the DNA of the embryonic culture medium.

      The chromosomal status of the embryo from an embryo biopsy of trophoectoderm will be
      established (usual clinical practice), the chromosomal endowment from the DNA of the
      embryonic culture medium will be determined, and the results using the NICS and the
      conventional invasive method (Preimplantation Genetic Testing for Aneuploidy [PGT-A]) will be
      compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Mosaicism</measure>
    <time_frame>At Day 5-6 after FIV</time_frame>
    <description>Presence of mosaicism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality value of NICS DLRS</measure>
    <time_frame>At Day 5-6 after FIV</time_frame>
    <description>Quality value of noninvasive chromosome screening (NICS) derivative Log Ratio Spread (DLRS)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chromosome Abnormality</condition>
  <condition>Abnormality</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Noninvasive chromosome screening</intervention_name>
    <description>Screening based on MALBAC-NGS technology</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Embryo culture medium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Couples who come to the study center to carry out a PGT-A cycle. Only couples that perform
        treatment using their own gametes will be selected and where the indication of PGT-A will
        be able to be advanced maternal age, failure of implantation, repeat abortion, male factor
        or structural chromosomal alterations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment by oocyte donation or own oocyte nd preimplantation genetic screening of
             aneuploidies (PGT-A).

          -  Embryonic cryopreservation.

          -  Informed consent signature

        Exclusion Criteria:

          -  Embryo transfer without embryo freezing

          -  Embryonic block.

          -  Bad embryo quality.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Belén Lledo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Bernabeu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Belén Lledo, PhD</last_name>
    <phone>+34965154000</phone>
    <email>blledo@institutobernabeu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belénn Lledó, PhD</last_name>
      <phone>+349154000</phone>
      <email>blledo@institutobernabeu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Belen Lledo</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Diagnosis</keyword>
  <keyword>Reproduction</keyword>
  <keyword>Chromosomal Endowment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

